

# John-William Sidhom

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5064831/publications.pdf>

Version: 2024-02-01

20  
papers

3,948  
citations

840119

11  
h-index

887659

17  
g-index

27  
all docs

27  
docs citations

27  
times ranked

7855  
citing authors

#	ARTICLE	IF	CITATIONS
1	DeepTCR is a deep learning framework for revealing sequence concepts within T-cell repertoires. Nature Communications, 2021, 12, 1605.	5.8	107
2	Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features. Npj Precision Oncology, 2021, 5, 38.	2.3	18
3	Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. , 2021, 9, e002345.		7
4	Deep learning identifies antigenic determinants of severe SARS-CoV-2 infection within T-cell repertoires. Scientific Reports, 2021, 11, 14275.	1.6	10
5	832â€...Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy. , 2021, 9, A872-A873.		0
6	Multiple genetic programs contribute to CD4 T cell memory differentiation and longevity by maintaining T cell quiescence. Cellular Immunology, 2020, 357, 104210.	1.4	8
7	Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell Reports Medicine, 2020, 1, 100139.	3.3	45
8	High-dimensional Cytometry (ExCYT) and Mass Spectrometry of Myeloid Infiltrate in Clinically Localized Clear Cell Renal Cell Carcinoma Identifies Novel Potential Myeloid Targets for Immunotherapy. Molecular and Cellular Proteomics, 2020, 19, 1850-1859.	2.5	2
9	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 1327-1337.	3.2	90
10	Integrative tumor and immune cell multi-omic analyses to predict melanoma response to immune checkpoint blockade.. Journal of Clinical Oncology, 2020, 38, 10009-10009.	0.8	1
11	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. , 2019, 7, 40.		42
12	A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cellâ€“Mediated Anticancer Activity. Cancer Immunology Research, 2019, 7, 428-442.	1.6	92
13	ExCYT: A Graphical User Interface for Streamlining Analysis of High-Dimensional Cytometry Data. Journal of Visualized Experiments, 2019, , .	0.2	4
14	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 2018, 378, 1976-1986.	13.9	1,495
15	ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis. Cancer Immunology Research, 2018, 6, 151-162.	1.6	42
16	Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells. Cancer Immunology Research, 2018, 6, 139-150.	1.6	172
17	The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunology Research, 2018, 6, 888-899.	1.6	118
18	Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth. ACS Nano, 2017, 11, 5417-5429.	7.3	130

#	ARTICLE	IF	CITATIONS
19	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell, 2017, 171, 934-949.e16.	13.5	1,515
20	Abstract 976: ImmunoMap: a novel bioinformatics tool for immune cell repertoire analysis. , 2017, , .		1